SNAP-25 gene polymorphisms and weight gain in schizophrenic patients

Journal of Psychiatric Research

Volumn 42, Issue 12, 2008, Pages 963-970

  Musil, Richard ^a   Spellmann, Ilja ^a   Riedel, Michael ^a   Dehning, Sandra ^a   Douhet, Anette ^a   Maino, Katja ^a   Zill, Peter ^a   Müller, Norbert ^a   Möller, Hans Jürgen ^a   Bondy, Brigitta ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Atypical antipsychotics; Pharmacogenetics; Polymorphism; Schizophrenia; SNAP 25 gene; Weight gain

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; BIPERIDEN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LORAZEPAM; LOW DENSITY LIPOPROTEIN; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; TRIACYLGLYCEROL; ZOPICLONE;

3' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INSOMNIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; MONOTHERAPY; POLYMERASE CHAIN REACTION; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; HUMANS; POLYMORPHISM, GENETIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25;

EID: 49149108655     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2007.11.003     Document Type: Article

References (30)

1. Basile V.S., Masellis M., De L.V., Meltzer H.Y., and Kennedy J.L. 759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain. Lancet 360 (2002) 1790-1791
2. Basile V.S., Masellis M., Potkin S.G., and Kennedy J.L. Pharmacogenomics in schizophrenia: the quest for individualized therapy. Human Molecular Genetics 11 (2002) 2517-2530
3. Basile V.S., Masellis M., McIntyre R.S., Meltzer H.Y., Lieberman J.A., and Kennedy J.L. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. Journal of Clinical Psychiatry 62 Suppl. 23 (2001) 45-66
4. Bottai T., Quintin P., and Perrin E. Antipsychotics and the risk of diabetes: a general data review. European Journal of Psychiatry 20 Suppl 4 (2005) S349-S357
5. Dudbridge F. A survey of current software for linkage analysis. Human Genomics 1 (2003) 63-65
6. Gonelle-Gispert C., Halban P.A., Niemann H., Palmer M., Catsicas S., and Sadoul K. SNAP-25a and -25b isoforms are both expressed in insulin-secreting cells and can function in insulin secretion. Biochemical Journal 339 Pt 1 (1999) 159-165
7. Hagg S., Lindblom Y., Mjorndal T., and Adolfsson R. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. International Clinical Psychopharmacology 21 (2006) 93-98
8. Jagadish M.N., Fernandez C.S., Hewish D.R., Macaulay S.L., Gough K.H., Grusovin J., et al. Insulin-responsive tissues contain the core complex protein SNAP-25 (synaptosomal-associated protein 25) A and B isoforms in addition to syntaxin 4 and synaptobrevins 1 and 2. Biochemical Journal 317 Pt 3 (1996) 945-954
9. Lindenmayer J.P., Volavka J., Lieberman J., Sheitman B., Citrome L., Chakos M., et al. Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial. Journal of Clinical Psychopharmacology 21 (2001) 448-453
10. Masand P.S., Culpepper L., Henderson D., Lee S., Littrell K., Newcomer J.W., et al. Metabolic and endocrine disturbances in psychiatric disorders: a multidisciplinary approach to appropriate atypical antipsychotic utilization. CNS Spectrums 10 suppl. 14-15 (2005)
11. Miller D.D., Ellingrod V.L., Holman T.L., Buckley P.F., and Arndt S. Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism. American Journal of Medical Genetics: Part B, Neuropsychiatric Genetics 133 (2005) 97-100
12. Muller D.J., Klempan T.A., De L.V., Sicard T., Volavka J., et al. The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. Neuroscience Letters 379 (2005) 81-89
13. Muller D.J., Muglia P., Fortune T., and Kennedy J.L. Pharmacogenetics of antipsychotic-induced weight gain. Pharmacological Research 49 (2004) 309-329
14. Nasrallah H.A., and Newcomer J.W. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. Journal of Clinical Psychopharmacology 24 (2004) S7-S14
15. Ness-Abramof R., and Apovian C.M. Drug-induced weight gain. Timely Topics in Medicine. Cardiovascular Diseases 9 (2005) E31
16. Park Y.W., Zhu S., Palaniappan L., Heshka S., Carnethon MR., and Heymsfield S.B. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Archives of Internal Medicine 163 (2003) 427-436
17. Perusse L., Rankinen T., Zuberi A., Chagnon Y.C., Weisnagel S.J., Argyropoulos G., et al. The human obesity gene map: the 2004 update. Obesity Research 13 (2005) 381-490
18. Reynolds G.P., Zhang Z., and Zhang X. Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. American Journal of Psychiatry 160 (2003) 677-679
19. Reynolds G.P., Zhang Z.J., and Zhang X.B. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 359 (2002) 2086-2087
20. Schiavo G., Stenbeck G., Rothman J.E., and Sollner T.H. Binding of the synaptic vesicle v-SNARE, synaptotagmin, to the plasma membrane t-SNARE, SNAP-25, can explain docked vesicles at neurotoxin-treated synapses. Proceedings of the National Academy of Sciences of the United States of America 94 (1997) 997-1001
21. Sollner T.H. Regulated exocytosis and SNARE function (Review). Molecular Membrane Biology 20 (2003) 209-220
22. Templeman L.A., Reynolds G.P., Arranz B., and San L. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenetics and Genomics 15 (2005) 195-200
23. Theisen F.M., Hinney A., Bromel T., Heinzel-Gutenbrunner M., Martin M., Krieg J.C., et al. Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and clozapine-induced weight gain among German schizophrenic individuals. Psychiatric Genetics 14 (2004) 139-142
24. Thompson P.M., Egbufoama S., and Vawter M.P. SNAP-25 reduction in the hippocampus of patients with schizophrenia. Progress in Neuropsychopharmacology & Biological Psychiatry 27 (2003) 411-417
25. Thompson P.M., Kelley M., Yao J., Tsai G., and van Kammen D.P. Elevated cerebrospinal fluid SNAP-25 in schizophrenia. Biological Psychiatry 53 (2003) 1132-1137
26. Thompson P.M., Sower A.C., and Perrone-Bizzozero N.I. Altered levels of the synaptosomal associated protein SNAP-25 in schizophrenia. Biological Psychiatry 43 (1998) 239-243
27. Tsai S.J., Hong C.J., Yu Y.W., and Lin C.H. -759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain. Lancet 360 (2002) 1790
28. Zhang Z, Zhang X, Yao Z, Chen J, Sun J, Yao H, et al. [Association of antipsychotic agent-induced weight gain with a polymorphism of the promotor region of the 5-HT2C receptor gene.] Zhonghua Yi Xue Za Zhi 2002;82:1097-101.
29. Zhang Z.J., Yao Z.J., Liu W., Fang Q., and Reynolds G.P. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. British Journal of Psychiatry 184 (2004) 58-62
30. Zipursky R.B., Gu H., Green A.I., Perkins D.O., Tohen M.F., McEvoy J.P., et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. British Journal of Psychiatry 187 (2005) 537-543